American Cancer Society Asks $5.69 Billion for NCI

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 11 No 4
Volume 11
Issue 4

WASHINGTON-The American Cancer Society (ACS) has offered a 13-point legislative agenda for 2002. The agenda backs President Bush’s request that Congress provide the National Institutes of Health $27.3 billion for fiscal year (FY) 2003, thus completing the doubling of the agency’s budget over 5 years.

WASHINGTON—The American Cancer Society (ACS) has offered a 13-point legislative agenda for 2002. The agenda backs President Bush’s request that Congress provide the National Institutes of Health $27.3 billion for fiscal year (FY) 2003, thus completing the doubling of the agency’s budget over 5 years.

ACS also wants the House and Senate to appropriate $5.69 billion for the National Cancer Institute, an increase of almost 36% above the $4.725 billion sought by Mr. Bush for FY2003, which begins on Oct. 1.

ACS also advocates $199.6 million (+24.4%) for the National Center for Minority Health and Health Disparities and $5 billion for the Centers for Disease Control and Prevention (CDC). The CDC figure represents an increase of $700 million (+16.2%), of which $1 billion (+33.7%) would fund the agency’s chronic disease prevention and health promotion program. ACS seeks $348 million to fund CDC’s cancer prevention and control efforts, an increase of 29.4% above the FY2002 budget

The ACS also urges Congress to provide $130 million (+28.7%) to fund the National Tobacco Control Plan/Office of Smoking and Health; $60 million (+118.1) for nutrition and physical activity; and $50 million (+32.3%) for CDC’s race initiatives.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
2 experts in this video
2 experts in this video
Treatment with lorlatinib might be effective regardless of the presence of central nervous system metastases, according to Misako Nagasaka, MD, PhD.
Most central nervous system events with lorlatinib were grade 1 or 2 in the phase 3 CROWN trial.
Related Content